A landscape of therapeutic cooperativity in KRAS mutant cancers reveals principles for controlling tumor evolution

Combinatorial inhibition of effector and feedback pathways is a promising treatment strategy for KRAS mutant cancers. However, the particular pathways that should be targeted to optimize therapeutic responses are unclear. Using CRISPR/Cas9, we systematically mapped the pathways whose inhibition coop...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cell Rep
Auteurs principaux: Anderson, Grace R., Winter, Peter S., Lin, Kevin H., Nussbaum, Daniel P., Cakir, Merve, Stein, Elizabeth M., Soderquist, Ryan S., Crawford, Lorin, Leeds, Jim C., Newcomb, Rachel, Stepp, Priya, Yip, Catherine, Wardell, Suzanne E., Tingley, Jennifer P., Ali, Moiez, Xu, Mengmeng, Ryan, Meagan, McCall, Shannon J., McRee, Autumn J., Counter, Christopher M., Der, Channing J., Wood, Kris C.
Format: Artigo
Langue:Inglês
Publié: 2017
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5567854/
https://ncbi.nlm.nih.gov/pubmed/28746882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2017.07.006
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires